TY  - JOUR 
AU  - San Miguel Izquierdo, Jesús Fernando
AU  - Bladé Creixenti, J
AU  - García Sanz, Ramón
PY  - 1999
SN  - 0390-6078
UR  - http://hdl.handle.net/10366/162237
AB  - [EN]Multiple myeloma (MM) accounts for about 10% of all hematologic malignancies. The standard treatment with intermittent courses of melphalan and prednisone (MP) was introduced more than 30 years ago and, since then there has been little improvement...
LA  - eng
PB  - Ferrata-Storti
KW  - Myeloma
KW  - Treatment
KW  - Chemotherapy
KW  - Autologous stem cell transplantation
KW  - Supportive therapy
KW  - Disease-Free Survival
KW  - Transplantation
KW  - Hematopoietic Stem Cell Transplantation
KW  - Transplantation Conditioning
KW  - Humans
KW  - Melphalan
KW  - Anemia
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Immunologic Factors
KW  - Prognosis
KW  - Osteolysis
KW  - Diphosphonates
KW  - Drug Resistance
KW  - Multiple Myeloma
KW  - Salvage Therapy
KW  - Myeloma Proteins
KW  - Interferon-alpha
KW  - Prednisone
KW  - Remission Induction
KW  - Bone Marrow Transplantation
TI  - Treatment of multiple myeloma.
T2  - Haematologica
VL  - 84
M2  - 36
ER  -